Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflammatory Bowel Disease

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Biologicals.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T

doi: 10.1016/j.biologicals.

Inflammatory Bowel Disease

Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis

Am J Gastroenterol.

Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR

doi: 10.1038/ajg.2017.470.

Inflammatory Bowel Disease

Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases

Gastroenterology.

Kochar B, Cai W, Cagan A, Ananthakrishnan AN

doi: 10.1053/j.gastro.2020.02.032.

Inflammatory Bowel Disease

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol.

Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ

doi: 10.1016/j.cgh.2019.02.044.

Inflammatory Bowel Disease

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications

J Crohns Colitis.

Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN

doi: 10.1093/ecco-jcc/jjaa050.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis.

Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN

doi: 10.1093/ibd/izz253.

RECOMMENDED

Inflammatory Bowel Disease

Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Clin Gastroenterol Hepatol.

Beaugerie L, Rahier JF, Kirchgesner J

doi: 10.1016/j.cgh.2020.02.009.

Inflammatory Bowel Disease

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease

Lancet Gastroenterol Hepatol.

Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J

doi: 10.1016/S2468-1253(19)30186-4.

Related content

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis

Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease

Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease